Get started
Author

Peter Ordentlich

Observed names: Ordentlich, P., Ordentlich, Peter, P Ordentlich, P. ORDENTLICH, P. Ordentlich, PETER ORDENTLICH, Peter Ordentlich (2703313)
Observed institutions: Universidad Complutense de Madrid, University of Maryland, Baltimore, Salk Institute for Biological Studies, Mayo Clinic, Children's Hospital of Philadelphia, The University of Texas MD Anderson Cancer Center, Howard Hughes Medical Institute, University of British Columbia, Johns Hopkins University, Medical College of Wisconsin, Centre Hospitalier Universitaire Sainte-Justine, University Hospital Regensburg, Massachusetts General Hospital, Fred Hutch Cancer Center, Sidney Kimmel Cancer Center, Dana-Farber Cancer Institute, National Cancer Institute, Mayo Clinic in Florida, Syndax Pharmaceuticals (United States), University of Colorado Anschutz, Universidad de Sevilla, University of Pennsylvania, University of Colorado Denver
ORCID: 0000-0002-6339-0996
Observed ORCID: 0000-0002-6339-0996
OpenAlex ID: A5021556154
Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors
2017 · Vinit Kumar, Laxminarasimha Donthireddy, et al. · Cancer Cell · 650
PDF
A histone deacetylase corepressor complex regulates the Notch signal transduction pathway
1998 · Hung-Ying Kao, Peter Ordentlich, et al. · Genes & Development · 579
PDF
A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR
2002 · Nancy L. Urizar, Amy B. Liverman, et al. · Science · 549
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
2023 · Ghayas C. Issa, Ibrahim Aldoss, et al. · Nature · 508
PDF
Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression
2000 · Hung-Ying Kao, Michael Downes, et al. · Genes & Development · 424
PDF
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma
2017 · Ashley Orillion, Ayumi Hashimoto, et al. · Clinical Cancer Research · 372
Sharp, an inducible cofactor that integrates nuclear receptor repression and activation
2001 · Yanhong Shi, Michael Downes, et al. · Genes & Development · 329
PDF
The Cytoplasmic Deacetylase HDAC6 Is Required for Efficient Oncogenic Tumorigenesis
2008 · Yi-Shan Lee, Kian-Huat Lim, et al. · Cancer Research · 260
PDF
Notch Inhibition of E47 Supports the Existence of a Novel Signaling Pathway
1998 · Peter Ordentlich, Arthur Lin, et al. · Molecular and Cellular Biology · 254
Regulation of PPARγ coactivator 1α (PGC-1α) signaling by an estrogen-related receptor α (ERRα) ligand
2004 · Patricia J. Willy, Ian R. Murray, et al. · Proceedings of the National Academy of Sciences · 196
Human deltex is a conserved regulator of Notch signalling
1998 · Kenji Matsuno, Deborah Eastman, et al. · Nature Genetics · 187
Identification of a Selective Inverse Agonist for the Orphan Nuclear Receptor Estrogen-Related Receptor α
2004 · Brett B. Busch, William C. Stevens,, et al. · Journal of Medicinal Chemistry · 173
Unique forms of human and mouse nuclear receptor corepressor SMRT
1999 · Peter Ordentlich, Michael Downes, et al. · Proceedings of the National Academy of Sciences · 171
The AF-1 Domain of the Orphan Nuclear Receptor NOR-1 Mediates Trans-activation, Coactivator Recruitment, and Activation by the Purine Anti-metabolite 6-Mercaptopurine
2003 · K. D. Senali Abayratna Wansa, Jonathan M. Harris, et al. · Journal of Biological Chemistry · 155
PDF
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
2024 · Daniel Wolff, Corey Cutler, et al. · New England Journal of Medicine · 154
Identification of a nuclear domain with deacetylase activity
2000 · Michael Downes, Peter Ordentlich, et al. · Proceedings of the National Academy of Sciences · 139
Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells
2003 · Åsa Wallén-Mackenzie, Alexander Mata de Urquiza, et al. · Genes & Development · 137
PDF
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy
2020 · Matthew D. Hellmann, Pasi A. Jänne, et al. · Clinical Cancer Research · 131
PDF
Identification of the Antineoplastic Agent 6-Mercaptopurine as an Activator of the Orphan Nuclear Hormone Receptor Nurr1
2003 · Peter Ordentlich, Yingzhuo Yan, et al. · Journal of Biological Chemistry · 117
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study
2022 · Carrie L. Kitko, Mukta Arora, et al. · Journal of Clinical Oncology · 104
PDF
Corepressors and Nuclear Hormone Receptor Function
2001 · P. Ordentlich, M. Downes, et al. · Current topics in microbiology and immunology · 76
The HDAC3–SMARCA4–miR-27a axis promotes expression of the PAX3:FOXO1 fusion oncogene in rhabdomyosarcoma
2018 · Narendra Bharathy, Noah E. Berlow, et al. · Science Signaling · 75
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
2016 · Yusuke Tomita, Min-Jung Lee, et al. · OncoImmunology · 72
HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression
2009 · Xiaoping Huang, Lizhi Gao, et al. · Cancer Research · 66
PDF
Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML
2021 · Bing Z. Carter, Wenjing Tao, et al. · Blood · 62
Works count: 172
Citation count: 6,887
H-index: 35
I10-index: 53
Year
Topic
Type